Sign up to be part of ‘world-first’ global health study into Parkinson’s disease
Author: Parkinson's Life editorsPublished: 18 February 2016
Prep: Cook: Serves:
A pioneering project invites people with Parkinson’s to take part in a ‘world-first’ global study and help change healthcare – with just their smartphones
Do you own a smartphone? Then you too can become a citizen scientist and help improve our insight and understanding of Parkinson’s disease in a new innovative global study.
The ‘100 for Parkinson’s’ global study is a pioneering project that promises to gather data about all aspects of living with Parkinson’s, including sleep quality, mood, exercise, diet and stress levels. According to the organisers, it is a ‘world-first, ethics-approved, people-centred’ project.
Using a smartphone app specially developed for the study by uMotif, participants will track 10 important health aspects over a period of 100 days.
This data will provide key information for a team of academic researchers from leading Parkinson’s charities to learn more about how different health factors affect the disease, and could lead to new discoveries about the condition. For example, we may discover how factors such as the time of day that medications are taken affect a patient’s reflexes.
How to take part
Visit www.100forparkinsons.com, download the uMotif app from the App Store or Google Play and enter the code ‘100fp’ to unlock the study.
You must be aged 18 or over, own a smartphone or tablet and be willing to track your health for 100 days and donate your data.
Are growth factors still an effective disease-modifying strategy?
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.